CALQUENCE DIN 02535696
Status: Marketed
Holder: ASTRAZENECA CANADA INC
Molecule: ACALABRUTINIB (ACALABRUTINIB MALEATE)
Available to quote
Health Canada record
| Active ingredient(s) | ACALABRUTINIB (ACALABRUTINIB MALEATE) 100 MG |
|---|---|
| Dosage form | Tablet |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | L01EL02 ACALABRUTINIB |
| Original market date | 01-May-2023 |
| Current status date | 01-May-2023 |
| Source | Health Canada DPD |
Establishment licence of the holder
AstraZeneca Canada Inc. — licence 100421, currently licensed, last inspection rating C (2023-06-12).
No Canadian shortage report is currently matched to this DIN.
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 30214 | 2023-02-27 | New Drug Submission (NDS) |